In a meta-analysis published in a recent issue in Angiology, 1 Wu et al found that several surrogate markers of subclinical atherosclerosis, including carotid-femoral pulse wave velocity (cfPWV), carotid intima-media thickness, and percentage flowmediated dilation, 3 vascular biomarkers, 2 are altered in patients with inflammatory bowel diseases (IBDs). These findings support the evidence for an elevated cardiovascular (CV) burden in patients with IBD, and they also help explain the IBD paradox-increased CV risk with a low prevalence of classic CV risk factors.
1
, and Pietro Castellino, MD 1 In a meta-analysis published in a recent issue in Angiology, 1 Wu et al found that several surrogate markers of subclinical atherosclerosis, including carotid-femoral pulse wave velocity (cfPWV), carotid intima-media thickness, and percentage flowmediated dilation, 3 vascular biomarkers, 2 are altered in patients with inflammatory bowel diseases (IBDs). These findings support the evidence for an elevated cardiovascular (CV) burden in patients with IBD, and they also help explain the IBD paradox-increased CV risk with a low prevalence of classic CV risk factors. 3 Moreover, these results support the hypothesis that inflammation is associated with functional and structural arterial stiffening in IBD and that antitumor necrosis factor a (anti-TNFa) therapy reduces arterial stiffness in IBD. [4] [5] [6] [7] However, Wu et al have not considered that the studies included in their metaanalysis calculated the cfPWV using different algorithms and path length. 7 Various algorithms applied to the same waveforms can result in differences in the calculated cfPWV values by up to 15% 8 ; variations in path length can result in differences in cfPWV values of up to 30%. 9 To clarify and to compensate for these differences in techniques, z scores, a validated technique to standardize and compare results of different studies, can be used. 7 A recent meta-analysis of cfPWV in patients with IBD (systematic review registration number: CRD42015017364) published by our group 7 included almost the same studies as the meta-analysis by Wu et al. 1 Using z scores, we reported that the mean cfPWV values in patients with ulcerative colitis and Crohn disease were 1.08 and 1.34 standard deviations higher, respectively, than the values for their respective control patients. These values corresponded to the 86th and 91st percentiles for cfPWV in controls, respectively. These findings are clinically relevant because in a meta-analysis, CV disease events increased by 30% per 1 standard deviation increase of cfPWV (95% confidence interval [CI]: 1.18-1.43) after adjustment for traditional risk factors. 10 Moreover, we reported in a meta-regression analysis that cfPWV was reduced in patients with IBD on anti-TNFa therapy (b: À2.6 m/s; 95% CI: À4.9 to À0.2 m/s; P ¼ .03). 
